Last edition
News about "Astellas Pharma"
Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer
Vir Biotechnology and Astellas are advancing VIR-5500 for late-line metastatic castration-resistant prostate cancer following encouraging preliminary Phase 1 findings.
Astellas Pharma | 12/10/2026 | By News Bureau
Astellas Pharma’s agreement aims to improve medicine affordability, strengthen critical drug supply chains and support continued investment in innovative therapies.
Astellas Pharma | 03/09/2026 | By Akanki | 137
Astellas Doses First Patient in Phase 3 ASP2138 Study for Gastric Cancer
Astellas doses the first patient in its phase 3 ASP2138 study for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction cancer.
Astellas Pharma | 26/08/2026 | By News Bureau
The European Commission has approved Padcev in combination with Keytruda as the first perioperative treatment for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer in Europe.
Astellas Pharma | 25/06/2026 | By News Bureau | 114
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Astellas Pharma | 21/04/2026 | By News Bureau | 178
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Astellas Pharma | 24/11/2025 | By Dineshwori | 223
Astellas and Japanese Foundation for Cancer Research to Accelerate Clinical Oncology Research
Through this collaboration, Astellas is committed to strengthening translational science and clinical research in order to deliver innovative new medicines.
Astellas Pharma | 04/04/2025 | By Aishwarya | 442
Astellas and YASKAWA to Establish Joint Venture Focused on Cell Therapy Manufacturing
The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot ‘Maholo’, developed by YASKAWA's subsidiary, Robotic Biology Institute.
Astellas Pharma | 06/03/2025 | By Aishwarya | 363
Axcelead DDP Signs Drug Discovery Service Deal with Astellas for Targeted Protein Degraders
Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLeadTM Platform and contribute to the generation of breakthrough new drug candidate compounds.
Astellas Pharma | 27/12/2024 | By Aishwarya | 379
Astellas Pharma and YASKAWA Sign MOU to Explore Innovative Cell Therapy Ecosystem
Astellas will contribute cell manufacturing technology, clinical development, and regulatory insights related to cell therapy, while YASKAWA will provide and develop robotics and factory automation technologies.
Astellas Pharma | 21/05/2024 | By Abha | 766
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy